UK Architects RMJM To Design $90m Biotech Facility In Beijing UK architecture firm RMJM has been appointed design architect for a state-of-the-art $US90 million biotechnology research and development centre in Beijing , it was announced recently. The new facility is for Genzyme Corp. The facility is to be built at Zhongguancun (ZGC) Life Science Park which is dedicated to academic and government research centres as well as pharmaceutical and biotechnology companies.
Source: www.medicalnewstoday.comBiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer BiPar Sciences, Inc. announced the expansion of Phase 2 clinical trial programs for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of BSI-201 that BiPar has launched in the past 6 months, expanding on on going trials in breast and brain cancer.
Source: www.medicalnewstoday.comLabels: No Prescription, Online Pharmacy
# posted by Network @ 3:00 AM
